HAIFA, Israel, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced the closing of its previously announced firm commitment underwritten public offering of 8,000,000 units, at a purchase price of $4.00 per unit, with each unit consisting of one share of the company's common stock and one warrant to purchase 0.35 of a share of the company's common stock, at an exercise price of $5.00 per share. The net proceeds to the company are approximately $30 million, assuming no exercise of the warrants and after deducting underwriting commissions and discounts and estimated offering expenses payable by the Company. Jefferies & Company, Inc. acted as sole book-running manager for the offering. Oppenheimer & Co. Inc. acted as co-lead manager for the offering. Needham & Company, LLC and Maxim Group LLC acted as co-managers for the offering. In addition, Leader Capital Markets Ltd. and Rothschild Inc. acted as financial advisors to the company in connection with the offering. The securities described above were offered by Pluristem pursuant to a "shelf" registration statement previously declared effective by the Securities and Exchange Commission (SEC) on October 20, 2011 (File No. 333-177009). Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained by sending a request to Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pluristem Therapeutics Inc.:Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe inflammatory and ischemic disorders. The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
CONTACT: Pluristem Therapeutics Inc. Daya Lettvin Investor & Media Relations Director Tel: +972-74-710-7131 Cell: +972-54-674-5580 MATAM Park, Building 20, Haifa 31905, Israel email@example.com